Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Metrics to compare | ROQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipROQPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.4x | −6.8x | −0.5x | |
PEG Ratio | −0.05 | −0.08 | 0.00 | |
Price/Book | 0.5x | 5.2x | 2.6x | |
Price / LTM Sales | - | 14.0x | 3.2x | |
Upside (Analyst Target) | - | 103.5% | 38.8% | |
Fair Value Upside | Unlock | −28.9% | 5.4% | Unlock |